| European Case Law Identifier: | ECLI:EP:BA:2008:T053407.20081125 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 25 November 2008 | ||||||||
| Case number: | T 0534/07 | ||||||||
| Application number: | 98928434.4 | ||||||||
| IPC class: | C12N 15/30 | ||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | D | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Reagents for vaccination which generate a CD8 T cell immune response | ||||||||
| Applicant name: | Oxxon Therapeutics Limited | ||||||||
| Opponent name: | Sanofi Pasteur OXFORD BIOMEDICA (UK) LTD. Therion Biologics Corporation POWDERJECT VACCINES INC. Danisco US Inc |
||||||||
| Board: | 3.3.08 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: | |||||||||
| Keywords: | Admissibility of appellant II's appeal - (no) - missing statement of grounds Admissibility of appellant I's appeal - (yes) Exclusion of representatives - (no) - no legal basis Novelty - (yes) Inventive step - (yes) Sufficiency of disclosure (yes) |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t070534eu1.html
Date retrieved: 17 May 2021
